Boehringer Ingelheim Joins Scleroderma Research Foundation’s Conquest Trial Platform


Pharma company is the second to join the project.

A research and development laboratory with scientists analyzing samples. The pharmaceutical and healthcare industry. Generative AI. Image Credit: Adobe Stock Images/Regina

Image Credit: Adobe Stock Images/Regina

The Scleroderma Research Foundation (SRF) announced that Boehringer Ingelheim will contribute an experimental agent to Conquest, one of its clinical trial programs. According to the company, the platform is specifically designed to efficiently advance promising treatments for scleroderma and to nominate agents that should progress from Phase IIb to Phase III clinical trials. Boehringer Ingelheim becomes the second company to contribute to the project after Sanofi was brought on in August.

"Boehringer Ingelheim has a rich history of innovation in the Interstitial Lung Disease (ILD) arena and is bringing their considerable experience and expertise to Conquest,” said Luke Envin, PhD, chairman of the Scleroderma Research Foundation, in a company press release. “The addition of a second deeply committed and highly sophisticated partner to Conquest is a strong validation of the platform's promise and value. Finally, with two partners, Conquest is fully subscribed and fully funded, ensuring that the platform will be able to execute against the vision of building a global community tuned to rapid and efficient clinical development of promising novel therapeutic agents for the high unmet needs of our scleroderma patients."

Reference: The Scleroderma Research Foundation (SRF) Announces Second Partnership for Conquest Trial Platform. PR Newswire. October 3, 2023. Accessed October 6, 2023.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.